The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients

Phase 1 Terminated 5 enrolled Sir Charles Gairdner Hospital The University of Western Australia · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Hypothesis: Intraperitoneal tPA and DNase is well tolerated at a number of different doses. Different doses of tPA and DNase will have a dose-related effect on inflammatory markers (CRP and intraperitoneal white cell count). Aims: 1. To examine the tolerability of different doses of intraperitoneal tPA and DNase compared to standard treatment. 2. To examine the changes in biochemical and clinical outcomes of PD Peritonitis with the addition of intraperitoneal tPA and DNase to usual therapy.

Timeline

Start: 2016-01-01
Primary completion: 2022-05-13
Completion: 2022-05-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alteplase	Protein / enzyme biologic	10 mg	Other
Subject	recombinant deoxyribonuclease	Unknown	5 mg	Other

Indications

No indication recorded.